Ubs Oconnor LLC Connect Biopharma Holdings LTD Transaction History

Ubs Oconnor LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.55 - $1.23 $132,965 - $297,358	-241,755 Reduced 47.34%	268,946 $147,000
Q1 2024 May 15, 2024	SELL	$1.01 - $1.74 $50,994 - $87,852	-50,490 Reduced 9.0%	510,701 $888,000
Q4 2023 Feb 14, 2024	SELL	$0.7 - $2.06 $29,896 - $87,980	-42,709 Reduced 7.07%	561,191 $662,000
Q2 2023 Aug 14, 2023	BUY	$1.01 - $1.25 $609,939 - $754,875	603,900 New	603,900 $670 Million
Q1 2023 May 15, 2023	BUY	$0.82 - $1.32 $5,378 - $8,657	6,559 Added 1.16%	574,148 $574,000
Q4 2022 Feb 14, 2023	SELL	$0.64 - $1.31 $29,658 - $60,708	-46,342 Reduced 7.55%	567,589 $0
Q3 2022 Nov 14, 2022	SELL	$0.8 - $1.65 $30,060 - $61,998	-37,575 Reduced 5.77%	613,931 $792 Million
Q2 2022 Aug 12, 2022	BUY	$0.56 - $3.25 $364,843 - $2.12 Million	651,506 New	651,506 $566,000

2.63M

Ticker CNTB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,015,800
Market Cap $125M
Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for t...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.